Using patient data including a total of 2772 infliximab drug levels from the pivotal IBD CT-P13 Part 1 [40] and Part 2 [43] studies, Hanzel et al. constructed a population pharmacokinetic model incorporating the effect of body weight, anti-drug antibodies and serum albumin, given their known influence on clearance of intravenous infliximab [53]. Here, ALB is linked to inflammatory bowel disease.